C19orf47 exon 9–AKT2 exon 2 chimeric RNA (C19orf47-AKT2) (C19orf47-AKT2)

The C19orf47e9–AKT2e2 chimeric RNA is a fusion transcript formed by the joining of exon 9 of the C19orf47 gene (also known as PIGBOS1) and exon 2 of the AKT2 gene. This specific chimeric RNA has been identified as a recurrent genetic alteration in prostate cancer, where it serves as a potential diagnostic and prognostic biomarker (Qin et al., 2017, Cancer Letters). The fusion typically results in the overexpression of the AKT2 protein or the production of a fusion protein that retains the functional kinase domain of AKT2. Because AKT2 is a critical component of the PI3K/AKT/mTOR signaling pathway, its dysregulation via this fusion promotes oncogenic processes such as increased cell proliferation, survival, and metabolic reprogramming (Zhang et al., 2020, Frontiers in Oncology). Therapeutic strategies targeting this chimeric product focus on the use of small-molecule AKT inhibitors, which aim to block the constitutive signaling driven by the AKT2 kinase domain (Davies et al., 2020, Molecular Cancer Therapeutics). The detection of this fusion transcript in clinical samples can help in the stratification of patients who may benefit from targeted kinase inhibitor therapy, particularly in cases of advanced or treatment-resistant disease.

Other names

PIGBOS1-AKT2C19orf47-AKT2 fusion transcriptC19orf47 exon 9-AKT2 exon 2 fusion

Inhibition of the AKT2 kinase domain activity to disrupt the PI3K/AKT signaling pathway.